Hypoxia Selectively Enhances Integrin α5β1 receptor expression in breast cancer to promote metastasis

Molecular Cancer Research

Volumn 15, Issue 6, 2017, Pages 723-734

  Ju, Julia A ^a,b   Godet, Inês ^a,b   Ye, I Chae ^a,b   Byun, Jungmin ^b   Jayatilaka, Hasini ^b   Lee, Sun Joo ^c   Xiang, Lisha ^c   Samanta, Debangshu ^c   Lee, Meng Horng ^b   Wu, Pei Hsun ^b   Wirtz, Denis ^a,b   Semenza, Gregg L ^a,c   Gilkes, Daniele M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROTEIN ITGA1; PROTEIN ITGA11; PROTEIN ITGA5; PROTEIN ITGB1; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BETA1 INTEGRIN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RISK FACTOR; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL HYPOXIA; CELL MOTION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTEGRIN ALPHA5BETA1; INTEGRIN BETA1; MICE, INBRED BALB C; MICE, INBRED NOD; PROMOTER REGIONS, GENETIC; SPHEROIDS, CELLULAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020405328     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0338     Document Type: Article

References (70)

1. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxiainducible factor-1 targeting. Cancer Res 2007;67:854-5.
2. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007;85:1301-7.
3. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 2007;26:311-7.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
5. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
6. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
7. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, et al. Hypoxia-inducible factor-2a correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008;68:9212-20.
8. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007;67:4157-63.
9. Li L, Lin X, Staver M, Shoemaker A, SemizarovD, Fesik SW, et al. Evaluating hypoxia-inducible factor-1a as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005;65:7249-58.
10. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1a is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007;67:563-72.
11. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012;31:1757-70.
12. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 2011;108: 16369-74.
13. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1a independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97: 1573-81.
14. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, GnantM, et al. Overexpression of hypoxia-inducible factor 1a is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
15. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1a expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006;12:4562-8.
16. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor 1a is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008;110:465-75.
17. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, et al. Overexpression of hypoxia-inducible factor HIF-1a predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-9.
18. Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL. Hypoxiainducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem 2013;288:10819-29.
19. Gilkes DM, Bajpai S, Wong CC, Chaturvedi P, Hubbi ME, Wirtz D, et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res 2013;11:456-66.
20. Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, et al. Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res 2013;73:3285-96.
21. Danen EH, van Rheenen J, FrankenW, Huveneers S, Sonneveld P, Jalink K, et al. Integrins control motile strategy through a Rho-cofilin pathway. J Cell Biol 2005;169:515-26.
22. Vleminckx K, Vakaet LJr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-19.
23. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 2014;14:430-9.
24. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010;123:4195-200.
25. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196:395-406.
26. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001;305:285-98.
27. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87.
28. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
29. Gilcrease MZ. Integrin signaling in epithelial cells. Cancer Lett 2007;247: 1-25.
30. Keely S, Glover LE, MacManus CF, Campbell EL, Scully MM, Furuta GT, et al. Selective induction of integrin b1 by hypoxia-inducible factor: implications for wound healing. FASEB J 2009;23: 1338-46.
31. Walton HL, Corjay MH, Mohamed SN, Mousa SA, Santomenna LD, Reilly TM. Hypoxia induces differential expression of the integrin receptors alpha(vbeta3) and alpha(vbeta5) in cultured human endothelial cells. J Cell Biochem 2000;78:674-80.
32. Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC. Hypoxia-inducible factor regulates avb3 integrin cell surface expression. Mol Biol Cell 2005;16:1901-12.
33. Kong T, Eltzschig HK, Karhausen J, Colgan SP, Shelley CS. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc Natl Acad Sci U S A 2004;101: 10440-5.
34. Kong T, Scully M, Shelley CS, Colgan SP. Identification of Pura as a new hypoxia response factor responsible for coordinated induction of the b2 integrin family. J Immunol 2007;179:1934-41.
35. Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, et al. Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A 2004;101:8132-7.
36. Saller MM, Prall WC, Docheva D, Schonitzer V, Popov T, Anz D, et al. Increased stemness and migration of human mesenchymal stem cells in hypoxia is associated with altered integrin expression. Biochem Biophys Res Commun 2012;423:379-85.
37. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
38. RingnerM, Fredlund E, Hakkinen J, BorgA, Staaf J.GOBO: gene expressionbased outcome for breast cancer online. PLoS One 2011;6:e17911.
39. Zhang H, Wong C, Wei H, Gilkes D, Korangath P, Chaturvedi P, et al. HIF-1- dependent expression of angiopoietin-like 4 and L1CAMmediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2011;31: 1757-70.
40. Hu H, Takano N, Xiang L, Gilkes DM, Luo W, Semenza GL. Hypoxiainducible factors enhance glutamate signaling in cancer cells. Oncotarget 2014;5:8853-68.
41. Wu PH, Giri A, Wirtz D. Statistical analysis of cell migration in 3D using the anisotropic persistent random walk model. Nat Protoc 2015;10: 517-27.
42. Jimenez Valencia AM, Wu PH, Yogurtcu ON, Rao P, DiGiacomo J, Godet I, et al. Collective cancer cell invasion induced by coordinated contractile stresses. Oncotarget 2015;6:43438-51.
43. Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxiainducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A 2014;111:E5429-38.
44. Kim DH, Wirtz D. Focal adhesion size uniquely predicts cell migration. FASEB J 2013;27:1351-61.
45. Kim DH, Wirtz D. Predicting how cells spread andmigrate: focal adhesion size does matter. Cell Adh Migr 2013;7:293-6.
46. WuPH, Giri A, Sun SX, Wirtz D. Three-dimensional cell migration does not follow a random walk. Proc Natl Acad Sci U S A 2014;111:3949-54.
47. Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife 2014;3:e01308.
48. ConklinMW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 2011;178:1221-32.
49. Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 2011;17: 1109-15.
50. Schedin P, Keely PJ. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol 2011;3:a003228.
51. Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 2013;44: 2028-37.
52. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440: 1222-6.
53. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med 2012;90: 803-15.
54. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013;73:1721-32.
55. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15:35-44.
56. Wong CC-L, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is amaster regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 2011;108:16369-74.
57. Giri A, Bajpai S, Trenton N, Jayatilaka H, Longmore GD, Wirtz D. The Arp2/ 3 complex mediates multigeneration dendritic protrusions for efficient 3- dimensional cancer cell migration. FASEB J 2013;27:4089-99.
58. Paul NR, Allen JL, Chapman A, Morlan-Mairal M, Zindy E, Jacquemet G, et al. a5b1 integrin recycling promotes Arp2/3-independent cancer cell invasion via the formin FHOD3. J Cell Biol 2015;210:1013-31.
59. Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D, et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci U S A 2014;111: E384-E93.
60. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1100-8.
61. Spangenberg C, Lausch EU, Trost TM, Prawitt D, May A, Keppler R, et al. ERBB2-mediated transcriptional up-regulation of the a5b1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res 2006;66:3715-25.
62. Damiano L, Stewart KM, Cohet N, Mouw JK, Lakins JN, Debnath J, et al. Oncogenic targeting of BRM drives malignancy through C/EBPb-dependent induction of a5 integrin. Oncogene 2014;33: 2441-53.
63. Orso F, Quirico L, Virga F, Penna E, Dettori D, Cimino D, et al. miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer. Cancer Res 2016;76:5151-62.
64. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, et al. A non- RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006;5:2271-80.
65. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, et al. Inhibition of integrin a5b1 function with a small peptide (ATN161) plus continuous 5FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104:496-503.
66. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, et al. Antiinvasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000;60:309-20.
67. Cianfrocca M, Kimmel K, Gallo J, Cardoso T, Brown M, Hudes G, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94:1621-6.
68. Barkan D, Chambers AF. b1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011;17:7219-23.
69. Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the a6Bb1 integrin to sustain breast cancer stem cells. Genes Dev 2015;29:1-6.
70. Ren W, Joshi R, Mathew P. Synthetic lethality in PTEN-mutant prostate cancer is induced by combinatorial PI3K/Akt and BCL-XL inhibition. Mol Cancer Res 2016;14:1176-81.